Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer

BACKGROUND: Patients with anaplastic thyroid cancer (ATC) have an extremely poor prognosis despite aggressive multimodal therapy. ATC has a high prevalence of BRAF(V600E) mutations and is associated with an immunosuppressive microenvironment; we previously demonstrated that the combination of BRAF i...

Descripción completa

Detalles Bibliográficos
Autores principales: Gunda, Viswanath, Gigliotti, Benjamin, Ndishabandi, Dorothy, Ashry, Tameem, McCarthy, Michael, Zhou, Zhiheng, Amin, Salma, Freeman, Gordon J., Alessandrini, Alessandro, Parangi, Sareh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251038/
https://www.ncbi.nlm.nih.gov/pubmed/30327563
http://dx.doi.org/10.1038/s41416-018-0296-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251038/
https://www.ncbi.nlm.nih.gov/pubmed/30327563
http://dx.doi.org/10.1038/s41416-018-0296-2

Ejemplares similares